Our Approach

banner_std

Our Approach

Ondek® is an Australian biotechnology company founded by Professor Barry Marshall, a world authority and co-recipient of the 2005 Nobel Prize for Medicine and Pathology for his co-discovery of the Helicobacter pylori bacterium. H. pylori is the only bacterium that naturally resides in the human stomach where it survives by regulating the host’s immune system to tolerate its presence.

Epidemiology studies have shown that there is an inverse correlation between the presence of H. pylori and the incidence of allergic asthma. In developing countries, where there is a high frequency of H. pylori, people have low levels of allergic asthma and in industrialised countries where less than 5% of children have H. pylori >25% of young children develop allergic asthma. Currently, there is no cure and limited treatments for allergic disorders, particularly in children. There is a mounting need for an effective treatment and improved management of allergy.

Ondek® has created and patented a derivative of H. pylori that has retained its immune regulatory properties to combat the escalating problem of allergy. The core product ImmBALANCE® will be used to develop a range of products for oral delivery to people suffering from allergy. Ondek’s ultimate aim is to develop products that will ensure infants and young children have a balanced immune system enabling the prevention of allergies. Our products will target eczema, food allergies and allergic asthma.




*World Allergy Organisation, White Book 2011